peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== Total thyroxine === Total thyroxine is rarely measured, having been largely superseded by free thyroxine tests. Total thyroxine (Total T4) is generally elevated in hyperthyroidism and decreased in hypothyroidism. It is usually slightly elevated in pregnancy secondary to increased levels of thyroid binding globulin (TBG). Total T4 is measured to see the bound and unbound levels of T4. The total T4 is less useful in cases where there could be protein abnormalities. The total T4 is less accurate due to the large amount of T4 that is bound. The total T3 is measured in clinical practice since the T3 has decreased amount that is bound as compared to T4. Reference ranges depend on the method of analysis. Results should always be interpreted using the range from the laboratory that performed the test. Example values are:
=== No development reported === Adapalene/minocycline (FCD-105) – combination of adapalene (retinoid) and minocycline (tetracycline antibiotic) Auriclosene (AgaDerm; AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422) – aganocide compound and antimicrobial Bermekimab (CA-18C3; CV-18C3; Hutruo; JNJ-77474462; MAB-p1; RA-18C3; T2-18C3; Xilonix) – monoclonal antibody against interleukin-1α BOS-356 (GSK-3008356) – diacylglycerol O-acyltransferase inhibitor Brilacidin (PMX-30063) – host defense protein (HDP) mimetic antibiotic Carbamide peroxide topical (E-0301) – disinfectant and bleaching agent CJM-112 – IL17A and IL17F inhibitor Clindamycin/tretinoin – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) Clindamycin/tretinoin – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) DMT-200 (DMT-210; DMT-220; SIG-990) – isoprenylcysteine analogue and various actions Estradiol valerate/dienogest (Climodien; Climodiène; Klimodien; Lafamme) – combination of estradiol valerate (estrogen) and dienogest (progestogen) Ethinylestradiol/chlormadinone acetate (Balianca; Belara; GRT4248) – combination of ethinylestradiol (estrogen) and chlormadinone acetate (progestogen) and a combined oral contraceptive Ethinylestradiol/drospirenone (Petibelle; SH-470; Yasmin; ZK-30595) – combination of ethinylestradiol (estrogen) and drospirenone (progestogen) GSK-1940029 – stearoyl-CoA desaturase inhibitor GT-20029 (AR-PROTAC) – androgen receptor degradation enhancer IP10-C8 – CD13 antigen inhibitor and dipeptidyl peptidase 4 (DPP4) inhibitor Minocycline extended release (Emrosi; Ximino) – tetracycline antibiotic Minocycline topical (HY01) – tetracycline antibiotic MTC-896 – melanocortin receptor antagonist Nitric oxide (Enovid; FabiSpray; NORS-0791; NORS-1002; NORS-2791; NORS-4002; NORS-6491; NORS) – nitric oxide donor ORG-101 (acne vulgaris vaccine; ORI-001; ORI-A-ce001) – immunostimulant, vaccine Radezolid (RX-01667; Rx-01_667; RX-103; RX-1741) – oxazolidone antibiotic Research programme: antimicrobial therapies - NovaBiotics – cell membrane permeability enhancers Research programme: synthetic cannabinoid therapeutics - Claritas Pharmaceuticals – cannabinoids (cannabinoid receptor modulators) Research programme: therapeutic antibody fragments - Kuur Therapeutics – various actions Silver dihydrogen citrate (SDC; Axenohl) – antiseptic/antibacterial Tazarotene topical (DFD-03) – retinoid X receptor agonist
== Clinical significance == The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications including social amnesia possibly related to autism. CD31 on endothelial cells binds to the CD38 receptor on natural killer cells for those cells to attach to the endothelium. CD38 on leukocytes attaching to CD31 on endothelial cells allows for leukocyte binding to blood vessel walls, and the passage of leukocytes through blood vessel walls. The cytokine interferon gamma and the Gram negative bacterial cell wall component lipopolysaccharide induce CD38 expression on macrophages. Interferon gamma strongly induces CD38 expression on monocytes. The cytokine tumor necrosis factor strongly induces CD38 on airway smooth muscle cells inducing cADPR-mediated Ca2+, thereby increasing dysfunctional contractility resulting in asthma. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism, as well as some genetically determined conditions. CD38 increases airway contractility hyperresponsiveness, is increased in the lungs of asthmatic patients, and amplifies the inflammatory response of airway smooth muscle of those patients.
Sources: en.wikipedia.org
== Chemistry == 2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine, is a substituted phenethylamine of the 2C family, also known as the 4-substituted 2,5-dimethoxyphenethylamines. It is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline found in peyote and certain other cacti.
In the first decade of the 21st century, what was called "age management medicine" was considered a field of alternative medicine, and, as of 2007, was not recognized by the American Medical Association. Other names at this time included "antiaging medicine" and "regenerative medicine". Age management medicine is controversial. The field is underregulated and supported by insufficient scientific evidence. People who practice it open themselves up to legal liability on grounds of negligence–malpractice, warranty issues, and product liability. The use of growth hormone has been frequently recommended; however, such use is associated with cancer. Age management medicine is often promoted by anti-aging practitioners specializing in nutritional supplements and hormone-replacement, a practice that may lead to harmful side-effects.
A radio-frequency quadrupole (RFQ) beam cooler is a device for particle beam cooling, especially suited for ion beams. It lowers the temperature of a particle beam by reducing its energy dispersion and emittance, effectively increasing its brightness (brilliance). The prevalent mechanism for cooling in this case is buffer-gas cooling, whereby the beam loses energy from collisions with a light, neutral and inert gas (typically helium). The cooling must take place within a confining field in order to counteract the thermal diffusion that results from the ion-atom collisions. The quadrupole mass analyzer (a radio frequency quadrupole used as a mass filter) was invented by Wolfgang Paul in the late 1950s to early 60s at the University of Bonn, Germany. Paul shared the 1989 Nobel Prize in Physics for his work. Samples for mass analysis are ionized, for example by laser (matrix-assisted laser desorption/ionization) or discharge (electrospray or inductively coupled plasma) and the resulting beam is sent through the RFQ and "filtered" by scanning the operating parameters (chiefly the RF amplitude). This gives a mass spectrum, or fingerprint, of the sample. Residual gas analyzers use this principle as well.
Endonucleases are enzymes that recognise and cleave nucleic acid segments and they can be used to direct DNA assembly. Of the different types of restriction enzymes, the type II restriction enzymes are the most commonly available and used because their cleavage sites are located near or in their recognition sites. Hence, endonuclease-mediated assembly methods make use of this property to define DNA parts and assembly protocols.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.